Probiogen AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Probiogen AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013197
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Probiogen AG (Probiogen), a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization’s services comprise therapeutic proteins/antibodies, viral vaccines, biosimilar and biobetter development. It offers contract cell line development, contract process development, contract manufacturing of GMP and non-GMP, protein analytics, and cell-based assays. It develops various technologies for optimized biopharmaceutical manufacturing and analysis. The organization also develops virusproduction system, adcc enhancement, yield enhancement, innovative bioassays and other technologies. Probiogen is headquartered in Berlin, Germany.

Probiogen AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Probiogen AG, Medical Devices Deals, 2011 to YTD 2017 9
Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Probiogen AG, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ProBioGen Enters into Co-Development Agreement with PT Bio Farma 11
ProBioGen Enters into Agreement with Zymeworks 12
Licensing Agreements 13
Chiome Bioscience Enters into Licensing Agreement with ProBioGen 13
ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 14
ProBioGen Enters into Licensing Agreement with Merus 15
ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 16
ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 17
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 18
ProBioGen Expands Licensing Agreement With Emergent BioSolutions For AGE1.CR Cell Line 19
Ceva Sante Animale Enters Into Licensing Agreement With ProBioGen For AGE1.CR Avian Cell Line 20
ProBioGen Enters Into Licensing Agreement With INHIBRX For GlymaxX ADCC Technology 21
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 22
Probiogen AG – Key Competitors 23
Probiogen AG – Key Employees 24
Probiogen AG – Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Probiogen AG, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Probiogen AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Probiogen AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Probiogen AG, Deals By Therapy Area, 2011 to YTD 2017 8
Probiogen AG, Medical Devices Deals, 2011 to YTD 2017 9
Probiogen AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ProBioGen Enters into Co-Development Agreement with PT Bio Farma 11
ProBioGen Enters into Agreement with Zymeworks 12
Chiome Bioscience Enters into Licensing Agreement with ProBioGen 13
ProBioGen Enters into Licensing Agreement with Eucodis Bioscience 14
ProBioGen Enters into Licensing Agreement with Merus 15
ProBioGen Enters into Licensing Agreement with Tizona Therapeutics 16
ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 17
ProBioGen Enters Into Licensing Agreement With Merus For GlymaxX ADCC Technology 18
ProBioGen Expands Licensing Agreement With Emergent BioSolutions For AGE1.CR Cell Line 19
Ceva Sante Animale Enters Into Licensing Agreement With ProBioGen For AGE1.CR Avian Cell Line 20
ProBioGen Enters Into Licensing Agreement With INHIBRX For GlymaxX ADCC Technology 21
Boehringer Ingelheim Enters Into Licensing Agreement With ProBioGen 22
Probiogen AG, Key Competitors 23
Probiogen AG, Key Employees 24

★海外企業調査レポート[Probiogen AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Brunswick Corporation (BC):企業の財務・戦略的SWOT分析
    Brunswick Corporation (BC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • CIGNA Corporation:戦略・SWOT・企業財務分析
    CIGNA Corporation - Strategy, SWOT and Corporate Finance Report Summary CIGNA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Mitsui O.S.K. Lines Ltd (9104):石油・ガス:M&Aディール及び事業提携情報
    Summary Mitsui O.S.K. Lines Ltd (MOL) is a global marine logistic company. It owns and operates dry bulkers, tankers, LNG carriers, containerships, ferries & coastal RoRo ships, cruise ships. The company’s dry bulkers transport dry bulk cargo such as iron ore, coal, grains, wood, wood chips, cement, …
  • Cosmo Pharmaceuticals NV (COPN):医療機器:M&Aディール及び事業提携情報
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • Tecan Group Ltd (TECN):製薬・医療:M&Aディール及び事業提携情報
    Summary Tecan Group Ltd (Tecan) is a provider of automated laboratory instruments and solutions for use in basic and translational research, clinical diagnostics, and drug discovery. The company develops, manufactures, and markets automated workflow solutions for laboratories and instrumentation sup …
  • Sammons Enterprises Inc:戦略・SWOT・企業財務分析
    Sammons Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Sammons Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • KPC Pharmaceuticals Inc (600422)-製薬・医療分野:企業M&A・提携分析
    Summary KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and botanical drugs. It also offers drugs such as xue …
  • Svenska Cellulosa Aktiebolaget:企業のM&A・事業提携・投資動向
    Svenska Cellulosa Aktiebolaget - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Svenska Cellulosa Aktiebolaget Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • PCM Inc:戦略・SWOT・企業財務分析
    PCM Inc - Strategy, SWOT and Corporate Finance Report Summary PCM Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • NanoString Technologies Inc (NSTG)-製薬・医療分野:企業M&A・提携分析
    Summary NanoString Technologies Inc (NanoString) is a provider of life science products and tools for translational research and molecular diagnostics. The company's products portfolio includes sprint profiler, Dx analysis system with flex, MAX analysis system, protein assays, solid tumor assays, ge …
  • Murata Manufacturing Co Ltd (6981):企業の財務・戦略的SWOT分析
    Murata Manufacturing Co Ltd (6981) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Utah Medical Products Inc (UTMD):企業の財務・戦略的SWOT分析
    Summary Utah Medical Products Inc (Utah Medical) is a medical device company that offers disposable and reusable products. The company offers blood pressure monitoring and blood management, gynecology, urology and electrosurgery, perinatology, respiratory and OEM products. Its blood pressure monitor …
  • The Home Depot, Inc.:企業のM&A・事業提携・投資動向
    The Home Depot, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Home Depot, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Pioneer Natural Resources Company:企業の戦略・SWOT・財務情報
    Pioneer Natural Resources Company - Strategy, SWOT and Corporate Finance Report Summary Pioneer Natural Resources Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Grand Gulf Energy Ltd (GGE):石油・ガス:M&Aディール及び事業提携情報
    Summary Grand Gulf Energy Ltd (Grand Gulf Energy), formerly Alto Energy International Ltd, is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in the US oil and gas basins. It holds interests in Napoleonville Salt Dome pro …
  • Senhwa Biosciences Inc (6492)-製薬・医療分野:企業M&A・提携分析
    Summary Senhwa Biosciences Inc (Senhwa) is a drug development company that develops small molecule drugs for the treatment of cancer. The company’s products include CX-5461 and CX-4945. Its CX-5461 is a p53 activating Pol I inhibitor and anticancer compound for treating hematological malignancies. S …
  • 3i Infotech Ltd (3IINFOTECH):企業の財務・戦略的SWOT分析
    3i Infotech Ltd (3IINFOTECH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • China Yangtze Power Co Ltd (600900):電力:M&Aディール及び事業提携情報
    Summary China Yangtze Power Co Ltd (CYPC), a subsidiary of China Three Gorges Corp is a renewable energy company that offers power distribution and sale services. The company offers services such as services of power distribution covering various areas including consultancy, energy procurement, dist …
  • Saint-Gobain Weber GmbH:企業の戦略・SWOT・財務分析
    Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report Summary Saint-Gobain Weber GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • EverPower Wind Holdings Inc:電力:M&Aディール及び事業提携情報
    Summary EverPower Wind Holdings Inc (Everpower), a subsidiary of Terra Firma Capital Partners Limited is a renewable energy company that owns, operates and develops utility scale wind energy projects. The company’s operating projects comprise big sky wind farm, highland wind farm, howard wind projec …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆